CVS Stock Recent News
CVS LATEST HEADLINES
CVS Health (CVS) concluded the recent trading session at $79.43, signifying a +0.14% move from its prior day's close.
Malcolm Ethridge, CIC Wealth Executive Vice President, joins 'Power Lunch' to discuss his investing take on three stocks: Visa, McCormick, and CVS.
The Investment Committee give you their top stocks to watch for the second half.
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
In the most recent trading session, CVS Health (CVS) closed at $78.06, indicating a +0.63% shift from the previous trading day.
CVS Group (AIM:CVSG), the veterinary service provider, has been downgraded to "sector perform" by analysts at RBC following the CMA's review of the industry. The group's price target has also been reduced from 2,100p to 1,200p, with the new price representing around a 15% premium to its current market value.
CVS Group (AIM:CVSG) PLC has said proposals are already available to address competition concerns in Britain's veterinary sector, after news of a probe stripped a quarter of its value on Tuesday. Pets at Home PLC, which was also dragged lower by the news of the regulatory investigation, argued such concerns did not relate to its own business model, meanwhile.
CVS Health is a lot more than just a chain of retail pharmacies. Aetna, one of America's largest health insurance companies, is a CVS Health subsidiary.
CVS Health reported solid full-year results for fiscal 2023, but already had to lower its guidance for fiscal 2024. During the 2023 investor day, CVS also lowered its long-term guidance but is still expecting earnings per share to grow at least 6%. The stock is still deeply undervalued, and we can bet on a reversion to the mean.
CVS Health and the healthcare services sector are facing numerous challenges in 2024, including cyber attacks, regulatory scrutiny, declining COVID-related sales, and lower CMS rates. The company is also dealing with higher medical care costs, implementation struggles, and leadership changes. Despite these seemingly temporary headwinds, it remains uncertain whether better times are ahead for CVS.